Halozyme Therapeutics, Inc.

HALO

US40637H1095

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2025-01-13 pm EST			5-day change	1st Jan Change
54.14 ^USD	+2.54%		+7.19%	+13.24%

Jan. 08	Sector Update: Health Care Stocks Rise Premarket Wednesday	MT
Jan. 08	Sector Update: Health Care	MT

Sector Update: Health Care Stocks Retreat Friday Afternoon

November 15, 2024 at 02:29 pm EST

This article is reserved for members

To unlock the article, REGISTER!

100% Free Registration

Already a customer? Log In

Latest news about Halozyme Therapeutics, Inc.

Sector Update: Health Care Stocks Rise Premarket Wednesday	Jan. 08	MT
Sector Update: Health Care	Jan. 08	MT
Halozyme Therapeutics, Inc., 2025 Guidance/Update Call, Jan 08, 2025	Jan. 08
Halozyme Therapeutics Raises 2025 Guidance; Shares Up Pre-Bell	Jan. 08	MT
Halozyme Therapeutics, Inc. Raises Earnings Guidance for the Full Year 2025	Jan. 08	CI
Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2024	Jan. 08	CI
Halozyme Therapeutics Insider Sold Shares Worth $500,060, According to a Recent SEC Filing	Jan. 07	MT
Halozyme Announces Takeda Receives Regulatory Approval for Hyqvia 10% Subcutaneous Injection Set with Enhanze in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia	Dec. 30	CI
Halozyme Therapeutics, Inc argenx's VYDURA with ENHANZE® is Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy	Dec. 30	CI
Evotec Refutes Halozyme Therapeutics' Reason for Buyout Bid Withdrawal	Nov. 24	MT
Sector Update: Health Care Stocks Edge Higher Late Afternoon	Nov. 22	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Nov. 22	MT
Halozyme withdraws offer for pharmaceutical researcher Evotec	Nov. 22	DP
Sector Update: Health Care Stocks Advance Premarket Friday	Nov. 22	MT
Halozyme Therapeutics Withdraws Proposal to Acquire Evotec	Nov. 22	MT
Sector Update: Health Care	Nov. 22	MT
Halozyme Therapeutics Withdraws Proposal to Acquire Evotec	Nov. 22	MT
Halozyme Therapeutics Withdraws Proposal to Acquire Evotec, Bloomberg Reports	Nov. 22	MT
Halozyme withdraws $2.1 billion buyout offer for Evotec	Nov. 22	RE
Halozyme Therapeutics, Inc. cancelled the acquisition of Evotec SE.	Nov. 21	CI
Evotec braces itself after Halozyme advances: Independence has priority	Nov. 19	DP
Evotec weak - Possible defense battle dampens takeover fantasy	Nov. 19	DP
Halozyme CEO: Evotec Is Poised for Growth	Nov. 18	MT
Sector Update: Health Care Stocks Slide Late Afternoon	Nov. 15	MT
Sector Update: Health Care Stocks Retreat Friday Afternoon	Nov. 15	MT

Chart Halozyme Therapeutics, Inc.

Duration

Period

HALO: Dynamic Chart

Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. The Companyâs ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, its commercially validated solution is used to facilitate the subcutaneous (SC) delivery of injected drugs and fluids, with a focus on reducing treatment burden for patients. It also develops, manufactures, and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED, partnered commercial products and ongoing product development programs with several pharmaceutical companies. It markets and sells Hylenex recombinant, which is a formulation of rHuPH20. It markets and sells its proprietary product XYOSTED for SC administration of testosterone replacement therapy (TRT) in adult males.

Employees

373

Sector

Pharmaceuticals

Calendar

2025-02-24 - Q4 2024 Earnings Release (Projected)

More about the company